368 related articles for article (PubMed ID: 33910450)
1. Development of molecular tools for diagnosis of Alzheimer's disease that are based on detection of amyloidogenic proteins.
Kulichikhin KY; Fedotov SA; Rubel MS; Zalutskaya NM; Zobnina AE; Malikova OA; Neznanov NG; Chernoff YO; Rubel AA
Prion; 2021 Dec; 15(1):56-69. PubMed ID: 33910450
[TBL] [Abstract][Full Text] [Related]
2. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
4. CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease.
Mouton-Liger F; Dumurgier J; Cognat E; Hourregue C; Zetterberg H; Vanderstichele H; Vanmechelen E; Bouaziz-Amar E; Blennow K; Hugon J; Paquet C
Alzheimers Res Ther; 2020 Jul; 12(1):88. PubMed ID: 32690068
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
6. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
[TBL] [Abstract][Full Text] [Related]
7. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
8. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
[TBL] [Abstract][Full Text] [Related]
9. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
10. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.
Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ
J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants.
Abu Rumeileh S; Lattanzio F; Stanzani Maserati M; Rizzi R; Capellari S; Parchi P
J Alzheimers Dis; 2017; 55(4):1471-1480. PubMed ID: 27886009
[TBL] [Abstract][Full Text] [Related]
12. Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Aβ42 levels.
Lattanzio F; Abu-Rumeileh S; Franceschini A; Kai H; Amore G; Poggiolini I; Rossi M; Baiardi S; McGuire L; Ladogana A; Pocchiari M; Green A; Capellari S; Parchi P
Acta Neuropathol; 2017 Apr; 133(4):559-578. PubMed ID: 28205010
[TBL] [Abstract][Full Text] [Related]
13. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease.
Perneczky R; Alexopoulos P;
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S425-S429.e1. PubMed ID: 24239250
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ
J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of tau deposition using
Bullich S; Mueller A; De Santi S; Koglin N; Krause S; Kaplow J; Kanekiyo M; Roé-Vellvé N; Perrotin A; Jovalekic A; Scott D; Gee M; Stephens A; Irizarry M
Alzheimers Res Ther; 2022 Jul; 14(1):105. PubMed ID: 35897078
[TBL] [Abstract][Full Text] [Related]
17. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
[TBL] [Abstract][Full Text] [Related]
18. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
19. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline.
Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q;
ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971
[TBL] [Abstract][Full Text] [Related]
20. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]